News tagged ‘Melanoma’ clear
- The use of monoclonal antibodies to activate an immune-system response
to abnormal cells resulted in a significant increase in survival time in
patients with metastatic melanoma, report Dana-Farber researchers.
Tags: ImmuneSystem, Melanoma, TranslationalResearch
- A duo of drugs can be safely administered and are potentially more effective than either drug alone for advanced, inoperable melanomas, according to a phase I clinical trial led by Dana-Farber investigators.
- Dana-Farber researchers found that combining the immune stimulator GM-CSF with the antibody drug ipilimumab prolonged survival in patients with metastatic melanoma and reduced the incidence of the most serious side effects.
- Scientists at Dana-Farber demonstrate that it’s possible, early in a tumor’s growth, to identify cancer genes that endow the tumor with the ability to metastasize. This is an important step toward developing prognostic tests for identifying early-stage tumors that are likely to spread and can be treated accordingly.
Tags: BasicResearch, Melanoma
- The U.S. Food and Drug Administration approved the use of ipilimumab for
the treatment of previously treated metastatic melanoma. It is the
first drug approved for metastatic, or advanced, melanoma in more than a
- A protein known as the "master watchman of the genome" for its ability to guard against cancer-causing DNA damage has been found to provide an entirely different level of cancer protection: By prompting the skin to tan in response to ultraviolet light from the sun, it deters the development of melanoma skin cancer, the fastest-increasing form of cancer in the world
- Nivolumab, a drug that unleashes the immune system to attack cancer, now shown to produce lasting remissions and hold the disease in check — for more than two years, in some cases — in many patients with advanced melanoma, according to a new study by Dana-Farber researchers and colleagues.
Tags: Melanoma, Immunotherapy
- Sunscreen is an important first line of protection, but can lose effectiveness over time, warn Dana-Farber's melanoma experts.
- Dana-Farber researchers found that in patients with advanced melanoma using the immunotherapy ipilimumab, presence of higher levels of the protein vascular endothelial growth factor (VEGF) in the blood was associated with a poorer response, suggesting that combining immunotherapy with VEGF inhibitors may be a potential option for these patients.
Tags: Melanoma, SkinCancer, Immunotherapy
- Dana-Farber scientists have
developed a technique that can cause white blood cells trained to attack tumors
to survive in patients’ bloodstreams for well over a year, and, in some cases,
without the need of other, highly toxic treatments.